로딩 중…
지수 로딩 중…
티움바이오
321550· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,090-5.21%
2026-06-19
Price Chart
티움바이오-25.36%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 122.86B KRW |
| Revenue | 13.13B KRW |
| Net Income | -16.16B KRW |
| Total Assets | 95.15B KRW |
| Net Assets | 33.72B KRW |
| Employees | 64 |
| Value | |
| P/B | 3.64x |
| P/S | 9.36x |
| FCF Yield | -12.67% |
| Profitability | |
| ROE | -47.91% |
| ROA | -16.98% |
| Op. Margin | -116.80% |
| Revenue Growth | 40.07% |
| Financial Health | |
| Debt Ratio | 282.14% |
| Total Debt | 29.28B KRW |
| FCF | -15.57B KRW |
| Cash | 3.38B KRW |
| Current Ratio | 1.01x |
| Performance | |
| 1Y Return | -25.36% |
| 1M Return | -54.81% |
| From 52W High | -70.15% |
| 1Y MDD | -68.87% |
| Trading | |
| Volume | 294,236 shares |
| Foreign Own. | 6.34% |
| Per Share | |
| EPS | -492 KRW |
| BPS | 1,169 KRW |
Company Info
TiumBio, established in 2016 and headquartered in Seongnam-si, Gyeonggi-do, is a research and development company focused on rare/intractable disease treatments, specially listed on KOSDAQ in 2019. In 2024, it expanded its business by a small merger with natural cosmetics company Petraon, creating the Petraon Care Lab division, while its Protium Science unit offers biopharmaceutical process development services. The company develops immunocancer drugs and endometriosis treatments through its new drug creation system, generating revenue from technology transfer and product sales.